FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308286763> ?p ?o ?g. }

• W4308286763 endingPage "e76" @default.
• W4308286763 startingPage "e71" @default.
• W4308286763 abstract "•ATP is a potent coronary vasodilator that is safe for stress CMR.•Splenic switch-off can serve as an indicator of stress success in ATP stress CMR.•The hyperemic response to ATP is quick and comparable to adenosine reported. AimTo evaluate the efficiency and safety of adenosine triphosphate (ATP) as a stress agent in a cohort of patients undergoing stress perfusion cardiac magnetic resonance imaging (CMRI).Materials and methodsThis retrospective study was conducted between December 2019 and October 2021. The study recruited patients who underwent stress perfusion CMRI using ATP as a vasodilator. Adverse events, such as chest pain, flushing, dyspnoea, headache, and splenic switch-off (SSO) phenomenon, were evaluated in the patients who underwent stress perfusion CMRI.ResultsThe study included 107 patients (age range: 53 ± 11 years; male:female, 62%:38%). The haemodynamic response (heart rate increased by ≥ 10 beats/min) was quick and observed within 2 minutes of ATP infusion. Scanning was stopped in three patients because of atrioventricular block. CMRI images of seven out of 104 patients were excluded from the final analysis because of inferior quality. During ATP infusion, 37/107 patients (35%) experienced mild adverse events, such as chest pain, flushing, dyspnoea, headache, and atrioventricular block. Myocardial infarction and bronchospasms were not observed during ATP infusion. SSO, a marker of adequate stress, was observed in 91% (94/103) of the patients who underwent stress perfusion CMRI.ConclusionsAs a coronary vasodilator, ATP was safe for stress perfusion CMRI. In addition, the adverse events during ATP infusion were mild, which were relieved within 2 minutes of ATP injection cessation. SSO could serve as an indicator of stress success in ATP stress perfusion CMRI. To evaluate the efficiency and safety of adenosine triphosphate (ATP) as a stress agent in a cohort of patients undergoing stress perfusion cardiac magnetic resonance imaging (CMRI). This retrospective study was conducted between December 2019 and October 2021. The study recruited patients who underwent stress perfusion CMRI using ATP as a vasodilator. Adverse events, such as chest pain, flushing, dyspnoea, headache, and splenic switch-off (SSO) phenomenon, were evaluated in the patients who underwent stress perfusion CMRI. The study included 107 patients (age range: 53 ± 11 years; male:female, 62%:38%). The haemodynamic response (heart rate increased by ≥ 10 beats/min) was quick and observed within 2 minutes of ATP infusion. Scanning was stopped in three patients because of atrioventricular block. CMRI images of seven out of 104 patients were excluded from the final analysis because of inferior quality. During ATP infusion, 37/107 patients (35%) experienced mild adverse events, such as chest pain, flushing, dyspnoea, headache, and atrioventricular block. Myocardial infarction and bronchospasms were not observed during ATP infusion. SSO, a marker of adequate stress, was observed in 91% (94/103) of the patients who underwent stress perfusion CMRI. As a coronary vasodilator, ATP was safe for stress perfusion CMRI. In addition, the adverse events during ATP infusion were mild, which were relieved within 2 minutes of ATP injection cessation. SSO could serve as an indicator of stress success in ATP stress perfusion CMRI." @default.
• W4308286763 created "2022-11-10" @default.
• W4308286763 creator A5006983596 @default.
• W4308286763 creator A5015936160 @default.
• W4308286763 creator A5019215507 @default.
• W4308286763 creator A5022525352 @default.
• W4308286763 creator A5051747731 @default.
• W4308286763 creator A5072119654 @default.
• W4308286763 creator A5084792129 @default.
• W4308286763 date "2023-02-01" @default.
• W4308286763 modified "2023-09-25" @default.
• W4308286763 title "Adenosine triphosphate (ATP): a safe and effective vasodilator for stress perfusion cardiac magnetic resonance imaging" @default.
• W4308286763 cites W1966812572 @default.
• W4308286763 cites W1970122309 @default.
• W4308286763 cites W2088443855 @default.
• W4308286763 cites W2114023904 @default.
• W4308286763 cites W2129884887 @default.
• W4308286763 cites W2132401137 @default.
• W4308286763 cites W2149888635 @default.
• W4308286763 cites W2528354637 @default.
• W4308286763 cites W2766205207 @default.
• W4308286763 cites W2900778683 @default.
• W4308286763 cites W2988904823 @default.
• W4308286763 cites W3008115610 @default.
• W4308286763 cites W3012802901 @default.
• W4308286763 cites W3030195953 @default.
• W4308286763 cites W3046167537 @default.
• W4308286763 cites W3047262395 @default.
• W4308286763 cites W3082592899 @default.
• W4308286763 cites W3103779492 @default.
• W4308286763 cites W3108600523 @default.
• W4308286763 cites W3113866673 @default.
• W4308286763 cites W3120617829 @default.
• W4308286763 cites W3134725295 @default.
• W4308286763 cites W3175509823 @default.
• W4308286763 doi "https://doi.org/10.1016/j.crad.2022.08.133" @default.
• W4308286763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36351853" @default.
• W4308286763 hasPublicationYear "2023" @default.
• W4308286763 type Work @default.
• W4308286763 citedByCount "0" @default.
• W4308286763 crossrefType "journal-article" @default.
• W4308286763 hasAuthorship W4308286763A5006983596 @default.
• W4308286763 hasAuthorship W4308286763A5015936160 @default.
• W4308286763 hasAuthorship W4308286763A5019215507 @default.
• W4308286763 hasAuthorship W4308286763A5022525352 @default.
• W4308286763 hasAuthorship W4308286763A5051747731 @default.
• W4308286763 hasAuthorship W4308286763A5072119654 @default.
• W4308286763 hasAuthorship W4308286763A5084792129 @default.
• W4308286763 hasBestOaLocation W43082867631 @default.
• W4308286763 hasConcept C120770815 @default.
• W4308286763 hasConcept C126322002 @default.
• W4308286763 hasConcept C126838900 @default.
• W4308286763 hasConcept C143409427 @default.
• W4308286763 hasConcept C146957229 @default.
• W4308286763 hasConcept C164705383 @default.
• W4308286763 hasConcept C197934379 @default.
• W4308286763 hasConcept C2776008845 @default.
• W4308286763 hasConcept C2776991684 @default.
• W4308286763 hasConcept C2778557577 @default.
• W4308286763 hasConcept C2778704086 @default.
• W4308286763 hasConcept C2909076160 @default.
• W4308286763 hasConcept C42219234 @default.
• W4308286763 hasConcept C500558357 @default.
• W4308286763 hasConcept C71924100 @default.
• W4308286763 hasConceptScore W4308286763C120770815 @default.
• W4308286763 hasConceptScore W4308286763C126322002 @default.
• W4308286763 hasConceptScore W4308286763C126838900 @default.
• W4308286763 hasConceptScore W4308286763C143409427 @default.
• W4308286763 hasConceptScore W4308286763C146957229 @default.
• W4308286763 hasConceptScore W4308286763C164705383 @default.
• W4308286763 hasConceptScore W4308286763C197934379 @default.
• W4308286763 hasConceptScore W4308286763C2776008845 @default.
• W4308286763 hasConceptScore W4308286763C2776991684 @default.
• W4308286763 hasConceptScore W4308286763C2778557577 @default.
• W4308286763 hasConceptScore W4308286763C2778704086 @default.
• W4308286763 hasConceptScore W4308286763C2909076160 @default.
• W4308286763 hasConceptScore W4308286763C42219234 @default.
• W4308286763 hasConceptScore W4308286763C500558357 @default.
• W4308286763 hasConceptScore W4308286763C71924100 @default.
• W4308286763 hasFunder F4320321001 @default.
• W4308286763 hasIssue "2" @default.
• W4308286763 hasLocation W43082867631 @default.
• W4308286763 hasLocation W43082867632 @default.
• W4308286763 hasOpenAccess W4308286763 @default.
• W4308286763 hasPrimaryLocation W43082867631 @default.
• W4308286763 hasRelatedWork W1495211148 @default.
• W4308286763 hasRelatedWork W2032391997 @default.
• W4308286763 hasRelatedWork W2052614528 @default.
• W4308286763 hasRelatedWork W2058975073 @default.
• W4308286763 hasRelatedWork W2071784603 @default.
• W4308286763 hasRelatedWork W2105545645 @default.
• W4308286763 hasRelatedWork W2129638289 @default.
• W4308286763 hasRelatedWork W2152363275 @default.
• W4308286763 hasRelatedWork W2316549451 @default.
• W4308286763 hasRelatedWork W99326604 @default.
• W4308286763 hasVolume "78" @default.
• W4308286763 isParatext "false" @default.
• W4308286763 isRetracted "false" @default.

• next